1)鶴尾 隆:分子標的治療薬の現状と展望.医学のあゆみ 215(7) : 601─605,2007
2)Tanaka S, Tsuda N, Sakamoto M, et al : Expression of tumor─rejection antigens in gynecologic cancers. Jpn J Cancer Res 91 : 1177─1184, 2000
3)Mochizuki K, Sato Y, Sakamoto M, et al : Immunological evaluation of vaccination with pre─designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen.Int J Oncology 25 : 121─31, 2004
4)藤原恵一,清水基弘,長尾昌二,他 : 分子標的治療の最新情報と展望.産婦人科の実際56 : 539─545,2007
5)Hurwitz H, Fehrenbacher L, Novotny W, et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 : 2335─2342, 2004
6)Giantonio BJ, Catalano PJ, Meropol NJ, et al : High─dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer : Results from the Eastern Cooperative Oncology Group(ECOG)study E3200. Abst No.2, Proc ASCO, 2005
7)Miller K, Wang M, Gralow J, et al : A randomized phase IIItrial of paclitaxel plus bevacizumab as first─line therapy for locally recurrent or metastatic breast cancer. E2100 Trial Symposium Presentation at ASCO, 2005
8)Sandler AB, Gray R, Brahmer J, et al : Randomized phase II/IIITrial of paclitaxel(P)plus carboplatin(C)with or without bevacizumab(NSC#704865)in patients with advanced non─squamous non─small cell lung cancer(NSCLC): An Eastern Cooperative Oncology Group(ECOG)Trial─ E4599 Abstract No.4, Proc ASCO, 2005
9)Burger RA, Sill M, Monk BJ, et al : Phase IItrial of bevacizumab in persistent or recurrent epithelial ovarian cancer(EOC)or primary peritoneal cancer(PPC): A Gynecologic Oncology Group(GOG)study. Abstract No.5009, Proc ASCO, 2005
10)Garcia AA, Oza AM, Hirte H, et al : Interim report of a phase IIclinical trial of bevacizumab(Bev)and low dose metronomic oral cyclophosphamide(mCTX)in recurrent ovarian(OC)and primary peritoneal carcinoma : A California Cancer Consortium Trial. Abstract No. 5000, Proc ASCO, 2005
11)Cannistra SA, Matulonis U, Penson R, et al : Bevacizumab in patients with advanced platinum─resistant ovarian cancer. Abstract No. 5006, Proc ASCO, 2006
12)Burger RA : Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25 : 2902─2908, 2007
13)Bookman MA, Darcy KM, Clarke─Pearson D, et al : Evaluation of monoclonal humanized anti─HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2 : a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 15 : 283─290, 2003
14)大柳文義,佐々木康綱 : 第I相臨床試験とトランスレーショナルリサーチ.最新医学58 : 24─28,2003
15)西條長宏,他(編) : Cancer Frontier : 分子標的治療2006.医薬ジャーナル社,2006
16)坂本 優,住浪義則,和氣徳夫,他 : 婦人科がんの発生─進展の分子機構解析に基づいた新しい分子診断・治療法の開発.平成12年度がん克服新10か年戦略プロジェクト研究報告書.pp180─195,厚生労働省,2001
17)坂本 優,加藤 紘,和氣徳夫,他 : 婦人科がんの発生─進展の分子機構解析に基づいた新しい分子診断・治療法の開発.平成13年度がん克服新10か年戦略プロジェクト研究報告書.pp197─210,厚生労働省,2002
18)坂本 優,加藤 紘,和氣徳夫,他 : 婦人科がんの発生─進展の分子機構解析に基づいた新しい分子診断・治療法の開発.平成14年度がん克服新10か年戦略プロジェクト研究報告書.pp182─196,厚生労働省,2003